Cx Precision Medicine’s technology is licensed from the University of North Texas Health Science Center (UNTHSC) laboratory of Sid O’Bryant, Ph. D., one of the world’s leading experts in blood-based biomarkers for Alzheimer’s disease and other neurodegenerative diseases. Dr. O’Bryant is the founder of the company and Professor of Pharmacology and Neuroscience at UNTHSC.
The company’s technology takes the guesswork out of initial diagnoses of neurodegenerative diseases and represents a paradigm shift away from one-size-fits-all treatments to a precision medicine approach, recognizing differences among patients based on their genetics, environment and lifestyle.
Arm primary care physicians with a more effective early-detection screen.
Develop companion diagnostics to aid in therapeutic matching for proprietary drugs, repurposed drugs, other disease states that may have adverse effects on AD patients.
Identify patients that will benefit from specific drugs.
Accelerate the development of new therapies for the treatment of AD.
